Cargando…
Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy
A 75-year-old male was diagnosed with carcinoma in-situ of the bladder. He failed standard therapy and was started on pembrolizumab to prevent the need for cystectomy. His malignancy recurred, and he was treated with intravesical valrubicin and gemcitabine/docetaxel. Three years after starting pembr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200038/ https://www.ncbi.nlm.nih.gov/pubmed/37220434 http://dx.doi.org/10.7759/cureus.37919 |
_version_ | 1785045054613618688 |
---|---|
author | Ober, Cecily E Jacocks, Charles E Osswald, Michael B |
author_facet | Ober, Cecily E Jacocks, Charles E Osswald, Michael B |
author_sort | Ober, Cecily E |
collection | PubMed |
description | A 75-year-old male was diagnosed with carcinoma in-situ of the bladder. He failed standard therapy and was started on pembrolizumab to prevent the need for cystectomy. His malignancy recurred, and he was treated with intravesical valrubicin and gemcitabine/docetaxel. Three years after starting pembrolizumab, he developed severe neutropenia and thrombocytopenia. He was treated for suspected auto-immune cytopenias but was later found to have acute promyelocytic leukemia on peripheral blood smear and cytometry. He was hospitalized, treated with all-trans retinoic acid and arsenic trioxide, and is currently in molecular remission. This case describes therapy-related acute promyelocytic leukemia (t-APL) diagnosed while on pembrolizumab. Pembrolizumab is an immune checkpoint inhibitor that exhibits anti-tumor effects. Development of hematologic malignancies after immune checkpoint inhibitor therapy is rare. The definitive etiology of our patient's t-APL is uncertain; however, it is more likely that he developed de novo acute promyelocytic leukemia (APL), which was suppressed by pembrolizumab and later revealed when pembrolizumab was discontinued. |
format | Online Article Text |
id | pubmed-10200038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-102000382023-05-22 Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy Ober, Cecily E Jacocks, Charles E Osswald, Michael B Cureus Internal Medicine A 75-year-old male was diagnosed with carcinoma in-situ of the bladder. He failed standard therapy and was started on pembrolizumab to prevent the need for cystectomy. His malignancy recurred, and he was treated with intravesical valrubicin and gemcitabine/docetaxel. Three years after starting pembrolizumab, he developed severe neutropenia and thrombocytopenia. He was treated for suspected auto-immune cytopenias but was later found to have acute promyelocytic leukemia on peripheral blood smear and cytometry. He was hospitalized, treated with all-trans retinoic acid and arsenic trioxide, and is currently in molecular remission. This case describes therapy-related acute promyelocytic leukemia (t-APL) diagnosed while on pembrolizumab. Pembrolizumab is an immune checkpoint inhibitor that exhibits anti-tumor effects. Development of hematologic malignancies after immune checkpoint inhibitor therapy is rare. The definitive etiology of our patient's t-APL is uncertain; however, it is more likely that he developed de novo acute promyelocytic leukemia (APL), which was suppressed by pembrolizumab and later revealed when pembrolizumab was discontinued. Cureus 2023-04-21 /pmc/articles/PMC10200038/ /pubmed/37220434 http://dx.doi.org/10.7759/cureus.37919 Text en Copyright © 2023, Ober et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Ober, Cecily E Jacocks, Charles E Osswald, Michael B Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy |
title | Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy |
title_full | Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy |
title_fullStr | Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy |
title_full_unstemmed | Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy |
title_short | Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy |
title_sort | therapy-related acute promyelocytic leukemia developed during pembrolizumab therapy |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200038/ https://www.ncbi.nlm.nih.gov/pubmed/37220434 http://dx.doi.org/10.7759/cureus.37919 |
work_keys_str_mv | AT obercecilye therapyrelatedacutepromyelocyticleukemiadevelopedduringpembrolizumabtherapy AT jacockscharlese therapyrelatedacutepromyelocyticleukemiadevelopedduringpembrolizumabtherapy AT osswaldmichaelb therapyrelatedacutepromyelocyticleukemiadevelopedduringpembrolizumabtherapy |